β-lactamase Characterization of Baseline Gram-Negative Pathogens from a Phase 3 Trial of Ceftazidime-Avibactam (CAZ-AVI) for the Treatment of Nosocomial Pneumonia
β-lactamase Characterization of Baseline Gram-Negative Pathogens from a Phase 3 Trial of Ceftazidime-Avibactam (CAZ-AVI) for the Treatment of Nosocomial Pneumonia. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P0408